The exercise price for warrants of series TO 3 has been determined

SciBase Holding AB (“SciBase” or the “Company”) announce today, after the end of the share price measurement period, that the exercise price for warrants of series TO 3 (the “Warrants” or “TO3”) has been determined to SEK 0.45 per share. The exercise period for the Warrants issued in connection with SciBase’s rights issue of units announced on November 12, 2024 begins on Monday, November 24, 2025, and runs up to, and including, December 5, 2025. Each Warrant entitles the holder to subscribe for one (1) new share in SciBase.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE DONE WITHOUT APPLICATION OF EXEMPTIONS FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Summary of terms and conditions for the Warrants and key dates

Each Warrant entitles the holder to subscribe for one (1) new share in SciBase at a subscription price that has been determined to SEK 0.45 per share. Upon full exercise of the Warrants, the Company will receive approximately SEK 53.4 million before deductions for issuing costs. The exercise period begins on Monday, November 24, 2025, and runs up to, and including, December 5, 2025. Note that an earlier deadline for exercise may apply to holders of Warrants held with a custodian. The last day of trading in the Warrants is December 3, 2025.

Full terms and conditions of the Warrants are available on the Company's website, www.scibase.com.

Shares and share capital

Upon full exercise of the Warrants, the number of shares in SciBase will increase by 118,757,229 shares, from 414,182,583 shares to a total of 532,939,812 shares, and the share capital will increase by SEK 5,937,861.45, from SEK 20 709 129,15 to SEK 26,646,990.60. The dilution upon exercise of all Warrants amounts to approximately 22.3 percent of the number of shares and votes in the Company.

Subscription price of TO3 higher than the market price

Holders of TO3 should note that the subscription price of the Warrants currently is higher than the price the SciBase share is traded at on Nasdaq First Borth Growth Market.

Exercise of Warrants

Custodian held Warrants

If the warrant holder has their Warrants in a share depository, in an investment savings account (Sw. Investeringssparkonto), or an endowment insurance (Sw. Kapitalförsäkring) (custodian-registered holdings), subscription and payment will take place with the nominee, who will provide further instructions on the procedure for exercising the Warrants. Warrant holders should contact their nominee well in advance for further instructions regarding the exercise of Warrants, as different nominees have different processing times.

Directly registered Warrants (VP account)

Application is made via a subscription form available by emailing to transactionsupport@dnbcarnegie.se alternatively info@scibase.com. Payment is made according to instructions on the application form. Both the subscription form and payment must be received by DNB Carnegie Investment Bank no later than December 5, 2025.

Trading of Warrants

Holders who do not wish to exercise their Warrants may sell them on Nasdaq First North Growth Market. The Warrants are traded until and including December 3, 2025, under the short name SCIB TO 3 and with ISIN SE0023594593. Warrants not exercised for subscription will expire without value.

For additional information, please contact:

Michael Colérus, CFO, phone +46 70 341 34 72

Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: certifiedadviser@carnegie.se

About SciBase

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

Important information

Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else.

This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Acquisition of Units in the Rights Issue should only be made on the basis of the information in the formal Prospectus published by the Company in connection with the Rights Issue and which is made available on the Company's website, www.scibase.com.

This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 ("Securities Act") and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.

Forward-looking statements

This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.

Läs mer på Cision